Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy

Leuk Res Rep. 2013 Aug 31;2(2):75-8. doi: 10.1016/j.lrr.2013.07.004. eCollection 2013.

Abstract

Most chronic myeloid leukemia (CML) patients show the Philadelphia chromosome (Ph) arising from the reciprocal t(9;22), but 5-10% present variants of this translocation involving different breakpoints besides 9q34 and 22q11. WE REPORT THE NON SIMULTANEOUS OCCURRENCE OF TWO DIFFERENT TYPES OF PH TRANSLOCATION IN A CML PATIENT: a t(9;22)(q34;q11) standard and a three-way variant t(9;11;22)(q34;p15;q11). Bone marrow cells with standard translocation did not have BCR/ABL kinase domain (KD) mutations and were sensitive to imatinib therapy. In contrast, bone marrow cells with the variant translocation showed two BCR/ABL KD mutations and were resistant to imatinib, thus inducing transformation to the blast phase and karyotype evolution.

Keywords: BCR/ABL KD mutation; CML; Tyrosine kinase inhibitors; Variant translocation.